Metronomic chemotherapy and immunotherapy in cancer treatment

Cancer Letters

Volumn 400, Issue , 2017, Pages 282-292

  Chen, Yu Li ^a,b   Chang, Ming Cheng ^a   Cheng, Wen Fang ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Cancer therapy; Immunotherapy; Metronomic chemotherapy

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; CAPECITABINE; CELECOXIB; CYCLOPHOSPHAMIDE; DACARBAZINE; DAUNORUBICIN; DENDRITIC CELL VACCINE; DNA VACCINE; DOXORUBICIN; ETORICOXIB; FLUOROURACIL; GEMCITABINE; INTERLEUKIN 12; INTERLEUKIN 2; METHOTREXATE; ONCOLYTIC ADENOVIRUS; PACLITAXEL; PIOGLITAZONE; RACOTUMOMAB; TEMOZOLOMIDE; VINBLASTINE; VINCRISTINE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; IMMUNOLOGIC FACTOR;

ANTIANGIOGENIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CANCER STEM CELL; GLIOMA; HUMAN; IMMUNOMODULATION; IMMUNOSURVEILLANCE; KIDNEY METASTASIS; LIVER CELL CARCINOMA; LOW DRUG DOSE; MAXIMUM TOLERATED DOSE; MELANOMA; METASTATIC BREAST CANCER; METASTATIC MELANOMA; METRONOMIC DRUG ADMINISTRATION; MULTIPLE CYCLE TREATMENT; MYELOID-DERIVED SUPPRESSOR CELL; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; PANCREAS TUMOR; PRIORITY JOURNAL; SHORT SURVEY; SOLID MALIGNANT NEOPLASM; TUMOR ASSOCIATED LEUKOCYTE; TUMOR ESCAPE; TUMOR MICROENVIRONMENT; TUMOR REGRESSION; ADVERSE EFFECTS; ANIMAL; DOSE RESPONSE; DRUG EFFECTS; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASMS; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PROCEDURES; TREATMENT OUTCOME; VASCULARIZATION;

ADMINISTRATION, METRONOMIC; ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; TREATMENT OUTCOME; TUMOR ESCAPE;

EID: 85013481656     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2017.01.040     Document Type: Review

References (128)

1. Caley, A., Jones, R., The principles of cancer treatment by chemotherapy. Surgery 30 (2012), 186–190.
2. Gasparini, G., Metronomic scheduling: the future of chemotherapy?. Lancet Oncol. 2 (2001), 733–740.
3. Schmiegelow, K., Nielsen, S.N., Frandsen, T.L., Nersting, J., Mercaptopurine/Methotrexate maintenance therapy of childhood acute lymphoblastic leukemia: clinical facts and fiction. J. Pediatr. Hematol. Oncol. 36 (2014), 503–517.
4. Skipper, H.E., Schabel, F.M. Jr., Mellett, L.B., Montgomery, J.A., Wilkoff, L.J., Lloyd, H.H., et al. Implications of biochemical, cytokinetic, pharmacologic, and toxicologic relationships in the design of optimal therapeutic schedules. Cancer Chemother. Rep. 54 (1970), 431–450.
5. Frei, E. III, Canellos, G.P., Dose: a critical factor in cancer chemotherapy. Am. J. Med. 69 (1980), 585–594.
6. Hanna, N.H., Einhorn, L.H., Testicular cancer–discoveries and updates. N. Engl. J. Med. 371 (2014), 2005–2016.
7. May, T., Goldstein, D.P., Berkowitz, R.S., Current chemotherapeutic management of patients with gestational trophoblastic neoplasia. Chemother. Res. Pract., 2011, 2011, 806256.
8. Pui, C.H., Mullighan, C.G., Evans, W.E., Relling, M.V., Pediatric acute lymphoblastic leukemia: where are we going and how do we get there?. Blood 120 (2012), 1165–1174.
9. Gerber, D.E., Schiller, J.H., Maintenance chemotherapy for advanced non-small-cell lung cancer: new life for an old idea. J. Clin. Oncol. 31 (2013), 1009–1020.
10. Tournigand, C., Cervantes, A., Figer, A., Lledo, G., Flesch, M., Buyse, M., et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer–a GERCOR study. J. Clin. Oncol. 24 (2006), 394–400.
11. Browder, T., Butterfield, C.E., Kräling, B.M., Shi, B., Marshall, B., O'Reilly, M.S., et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 60 (2000), 1878–1886.
12. Klement, G.L., Baruchel, S., Rak, J., Man, S., Clark, K., Hicklin, D.J., et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Invest. 105 (2000), R15–R24.
13. Hanahan, D., Bergers, G., Bergsland, E., Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J. Clin. Invest. 105 (2000), 1045–1047.
14. Bertolini, F., Paul, S., Mancuso, P., Monestiroli, S., Gobbi, A., Shaked, Y., et al. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res. 63 (2003), 4342–4346.
15. Shaked, Y., Ciarrocchi, A., Franco, M., Lee, C.R., Man, S., Cheung, A.M., et al. Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 313 (2006), 1785–1787.
16. Gnoni, A., Silvestris, N., Licchetta, A., Santini, D., Scartozzi, M., Ria, R., et al. Metronomic chemotherapy from rationale to clinical studies: a dream or reality?. Crit. Rev. Oncol. Hematol. 95 (2015), 46–61.
17. Bryniarski, K., Szczepanik, M., Ptak, M., Zemelka, M., Ptak, W., Influence of cyclophosphamide and its metabolic products on the activity of peritoneal macrophages in mice. Pharmacol. Rep. 61 (2009), 550–557.
18. Ghiringhelli, F., Menard, C., Puig, P.E., Ladoire, S., Roux, S., Martin, F., et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol. Immunother. 56 (2007), 641–648.
19. Michels, T., Shurin, G.V., Naiditch, H., Sevko, A., Umansky, V., Shurin, M.R., Paclitaxel promotes differentiation of myeloid-derived suppressor cells into dendritic cells in vitro in a TLR4-independent manner. J. Immunotoxicol. 9 (2012), 292–300.
20. Kaneno, R., Shurin, G.V., Tourkova, I.L., Shurin, M.R., Chemomodulation of human dendritic cell function by antineoplastic agents in low noncytotoxic concentrations. J. Transl. Med., 7, 2009, 58.
21. Bergers, G., Benjamin, L.E., Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer 3 (2003), 401–410.
22. Moserle, L., Amadori, A., Indraccolo, S., The angiogenic switch: implications in the regulation of tumor dormancy. Curr. Mol. Med. 9 (2009), 935–941.
23. André, N., Pasquier, E., Response to 'Intermittent androgen blockade should be regarded as standard therapy in prostate cancer'. Nat. Clin. Pract. Oncol., 6, 2009, E1.
24. Chuu, C.P., Hiipakka, R.A., Fukuchi, J., Kokontis, J.M., Liao, S., Androgen causes growth suppression and reversion of androgenindependent prostate cancer xenografts to an androgen-stimulated phenotype in athymic mice. Cancer Res. 65 (2005), 2082–2084.
25. Sabnis, G.J., Macedo, L.F., Goloubeva, O., Schayowitz, A., Brodie, A.M., Stopping treatment can reverse acquired resistance to letrozole. Cancer Res. 68 (2008), 4518–4524.
26. Munoz, R., Shaked, Y., Bertolini, F., Emmenegger, U., Man, S., Kerbel, R.S., Anti-angiogenic treatment of breast cancer using metronomic low-dose chemotherapy. Breast 14 (2005), 466–479.
27. Chow, A., Wong, A., Francia, G., Man, S., Kerbel, R.S., Emmenegger, U., Preclinical analysis of resistance and cross-resistance to low-dose metronomic chemotherapy. Invest. New Drugs 32 (2014), 47–59.
28. Cruz-Muñoz, W., Di Desidero, T., Man, S., Xu, P., Jaramillo, M.L., Hashimoto, K., et al. Analysis of acquired resistance to metronomic oral topotecan chemotherapy plus pazopanib after prolonged preclinical potent responsiveness in advanced ovarian cancer. Angiogenesis 17 (2014), 661–673.
29. Kubisch, R., Meissner, L., Krebs, S., Blum, H., Günther, M., Roidl, A., et al. A comprehensive gene expression analysis of resistance formation upon metronomic cyclophosphamide therapy. Transl. Oncol. 6 (2013), 1–9.
30. Mellman, I., Coukos, G., Dranoff, G., Cancer immunotherapy comes of age. Nature 480 (2011), 480–489.
31. Emens, L.A., Middleton, G., The interplay of immunotherapy and chemotherapy: harnessing potential synergies. Cancer Immunol. Res. 3 (2015), 436–443.
32. Kerbel, R.S., Kamen, B.A., The anti-angiogenic basis of metronomic chemotherapy. Nat. Rev. Cancer 4 (2004), 423–436.
33. Folkman, J., Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285 (1971), 1182–1186.
34. Asahara, T., Murohara, T., Sullivan, A., Silver, M., van der Zee, R., Li, T., et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 275 (1997), 964–967.
35. Rafii, S., Lyden, D., Benezra, R., Hattori, K., Heissig, B., Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy?. Nat. Rev. Cancer 2 (2002), 826–835.
36. Hida, K., Ohga, N., Akiyama, K., Maishi, N., Hida, Y., Heterogeneity of tumor endothelial cells. Cancer Sci. 104 (2013), 1391–1395.
37. Carmeliet, P., Jain, R.K., Angiogenesis in cancer and other diseases. Nature 407 (2000), 249–257.
38. Volpert, O.V., Tolsma, S.S., Pellerin, S., Feige, J.J., Chen, H., Mosher, D.F., et al. Inhibition of angiogenesis by thrombospondin-2. Biochem. Biophys. Res. Commun. 217 (1995), 326–332.
39. Bergers, G., Hanahan, D., Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer 8 (2008), 592–603.
40. Takahashi, N., Haba, A., Matsuno, F., Seon, B.K., Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide. Cancer Res. 61 (2001), 7846–7854.
41. Hamano, Y., Sugimoto, H., Soubasakos, M.A., Kieran, M., Olsen, B.R., Lawler, J., et al. Thrombospondin-1 associated with tumor microenvironment contributes to low-dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth suppression. Cancer Res. 64 (2004), 1570–1574.
42. Vacca, A., Iurlaro, M., Ribatti, D., Minischetti, M., Nico, B., Ria, R., et al. Antiangiogenesis is produced by nontoxic doses of vinblastine. Blood 94 (1999), 4143–4155.
43. Vacca, A., Ribatti, D., Iurlaro, M., Merchionne, F., Nico, B., Ria, R., et al. Docetaxel versus paclitaxel for antiangiogenesis. J. Hematother. Stem Cell Res. 11 (2002), 103–118.
44. Bocci, G., Nicolaou, K.C., Kerbel, R.S., Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res. 62 (2002), 6938–6943.
45. Wang, J., Lou, P., Lesniewski, R., Henkin, J., Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly. Anticancer Drugs 14 (2003), 13–19.
46. Grant, D.S., Williams, T.L., Zahaczewsky, M., Dicker, A.P., Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere). Int. J. Cancer 104 (2003), 121–129.
47. Klement, G.L., Huang, P., Mayer, B., Green, S.K., Man, S., Bohlen, P., et al. Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts. Clin. Cancer Res. 8 (2002), 221–232.
48. Bocci, G., Francia, G., Man, S., Lawler, J., Kerbel, R.S., Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc. Natl. Acad. Sci. U.S.A. 100 (2003), 12917–12922.
49. Dawson, D.W., Pearce, S.F., Zhong, R., Silverstein, R.L., Frazier, W.A., Bouck, N.P., CD36 mediates the in vitro inhibitory effects of thrombospondin-1 on endothelial cells. J. Cell Biol. 138 (1997), 707–717.
50. Allegrini, G., Falcone, A., Fioravanti, A., Barletta, M.T., Orlandi, P., Loupakis, F., et al. A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients. Br. J. Cancer 98 (2008), 1312–1319.
51. Bocci, G., Falcone, A., Fioravanti, A., Orlandi, P., Di Paolo, A., Fanelli, G., et al. Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib. Br. J. Cancer 98 (2008), 1619–1629.
52. Wu, H., Xin, Y., Zhao, J., Sun, D., Li, W., Hu, Y., et al. Metronomic docetaxel chemotherapy inhibits angiogenesis and tumor growth in a gastric cancer model. Cancer Chemother. Pharmacol. 68 (2011), 879–887.
53. Zhang, M., Tao, W., Pan, S., Sun, X., Jiang, H., Low-dose metronomic chemotherapy of paclitaxel synergizes with cetuximab to suppress human colon cancer xenografts. Anticancer Drugs 20 (2009), 355–363.
54. Jiang, H., Tao, W., Zhang, M., Pan, S., Kanwar, J.R., Sun, X., Low-dose metronomic paclitaxel chemotherapy suppresses breast tumors and metastases in mice. Cancer Invest. 28 (2010), 74–84.
55. Garcia-Barros, M., Paris, F., Cordon-Cardo, C., Lyden, D., Rafii, S., Haimovitz-Friedman, A., et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 300 (2003), 1155–1159.
56. Hirata, S., Matsubara, T., Saura, R., Tateishi, H., Hirohata, K., Inhibition of in vitro vascular endothelial cell proliferation and in vivo neovascularization by low-dose methotrexate. Arthritis Rheum. 32 (1989), 1065–1073.
57. Belotti, D., Vergani, V., Drudis, T., Borsotti, P., Pitelli, M.R., Viale, G., et al. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin. Cancer Res. 2 (1996), 1843–1849.
58. Rapisarda, A., Uranchimeg, B., Scudiero, D.A., Selby, M., Sausville, E.A., Shoemaker, R.H., et al. Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res. 62 (2002), 4316–4324.
59. Kummar, S., Raffeld, M., Juwara, L., Horneffer, Y., Strassberger, A., Allen, D., et al. Multihistology, target-driven pilot trial of oral topotecan as an inhibitor of hypoxia-inducible factor-1α in advanced solid tumors. Clin. Cancer Res. 17 (2011), 5123–5131.
60. Lee, K., Qian, D.Z., Rey, S., Wei, H., Liu, J.O., Semenza, G.L., Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells. Proc. Natl. Acad. Sci. U.S.A. 106 (2009), 2353–2358.
61. Kareva, I., Waxman, D.J., Klement, G., Metronomic chemotherapy: an attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance. Cancer Lett. 358 (2015), 100–106.
62. Hanahan, D., Weinberg, R.A., Hallmarks of cancer: the next generation. Cell 144 (2011), 646–674.
63. Smyth, M.J., Dunn, G.P., Schreiber, R.D., Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv. Immunol. 90 (2006), 1–50.
64. Yamaguchi, T., Sakaguchi, S., Regulatory T cells in immune surveillance and treatment of cancer. Semin. Cancer Biol. 16 (2006), 115–123.
65. Ostrand-Rosenberg, S., Sinha, P., Myeloid-derived suppressor cells: linking inflammation and cancer. J. Immunol. 182 (2009), 4499–4506.
66. Curiel, T.J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10 (2004), 942–949.
67. Sato, E., Olson, S.H., Ahn, J., Bundy, B., Nishikawa, H., Qian, F., et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc. Natl. Acad. Sci. U.S.A. 102 (2005), 18538–18543.
68. Swann, B.J., Smyth, M.J., Immune surveillance of tumors. J. Clin. Invest. 117 (2007), 1137–1146.
69. Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 13 (2007), 1050–1059.
70. Mackall, C.L., Fleisher, T.A., Lymphocyte depletion during treatment with intensive chemotherapy for cancer. Blood 84 (1994), 2221–2228.
71. André, N., Carré, M., Pasquier, E., Metronomics: towards personalized chemotherapy?. Nat. Rev. Clin. Oncol. 11 (2014), 413–431.
72. Martinez, F.O., Sica, A., Mantovani, A., Locati, M., Macrophage activation and polarization. Front. Biosci. 13 (2008), 453–461.
73. Mills, C.D., Kincaid, K., Alt, J.M., Heilman, M.J., Hill, A.M., M-1/M-2 macrophages and the Th1/Th2 paradigm. J. Immunol. 164 (2000), 6166–6173.
74. Bracci, L., Schiavoni, G., Sistigu, A., Belardelli, F., Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. Cell Death Differ. 21 (2014), 15–25.
75. Lutsiak, M.E., Semnani, R.T., De Pascalis, R., Kashmiri, S.V., Schlom, J., Sabzevari, H., Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 105 (2005), 2862–2868.
76. Zhao, J., Cao, Y., Lei, Z., Yang, Z., Zhang, B., Huang, B., Selective depletion of CD4+CD25+Foxp3+ regulatory T cells by low-dose cyclophosphamide is explained by reduced intracellular ATP levels. Cancer Res. 70 (2010), 4850–4858.
77. Shevchenko, I., Karakhanova, S., Soltek, S., Link, J., Bayry, J., Werner, J., et al. Low-dose gemcitabine depletes regulatory T cells and improve survival in the orthotopic Panc02 model of pancreatic cancer. Int. J. Cancer 133 (2013), 98–107.
78. Tongu, M., Harashima, N., Monma, H., Inao, T., Yamada, T., Kawauchi, H., et al. Metronomic chemotherapy with low-dose cyclophosphamide plus gemcitabine can induce anti-tumor T cell immunity in vivo. Cancer Immunol. Immunother. 62 (2013), 383–391.
79. Salem, M.L., Al-Khami, A.A., El-Nagaar, S.A., Zidan, A.A., Al-Sharkawi, I.M., Marcela, D.C., et al. Kinetics of rebounding of lymphoid and myeloid cells in mouse peripheral blood, spleen and bone marrow after treatment with cyclophosphamide. Cell Immunol. 276 (2012), 67–74.
80. Angulo, I., de las Heras, F.G., García-Bustos, J.F., Gargallo, D., Muñoz-Fernández, M.A., Fresno, M., Nitric oxide-producing CD11b(+)Ly-6G(Gr-1)(+)CD31(ER-MP12)(+) cells in the spleen of cyclophosphamide-treated mice: implications for T-cell responses in immunosuppressed mice. Blood 95 (2000), 212–220.
81. Tesniere, A., Apetoh, L., Ghiringhelli, F., Joza, N., Panaretakis, T., Kepp, O., et al. Immunogenic cancer cell death: a key-lock paradigm. Curr. Opin. Immunol. 20 (2008), 504–511.
82. Obeid, M., Tesniere, A., Panaretakis, T., Tufi, R., Joza, N., van Endert, P., et al. Ecto-calreticulin in immunogenic chemotherapy. Immunol. Rev. 220 (2007), 22–34.
83. Ghiringhelli, F., Apetoh, L., Tesniere, A., Aymeric, L., Ma, Y., Ortiz, C., et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat. Med. 15 (2009), 1170–1178.
84. Kaneno, R., Shurin, G.V., Kaneno, F.M., Naiditch, H., Luo, J., Shurin, M.R., Chemotherapeutic agents in low noncytotoxic concentrations increase immunogenicity of human colon cancer cells. Cell Oncol. (Dordr) 34 (2011), 97–106.
85. Correale, P., Aquino, A., Giuliani, A., Pellegrini, M., Micheli, L., Cusi, M.G., et al. Treatment of colon and breast carcinoma cells with 5-fluorouracil enhances expression of carcinoembryonic antigen and susceptibility to HLA-A(*)02.01 restricted, CEA-peptide-specific cytotoxic T cells in vitro. Int. J. Cancer 104 (2003), 437–445.
86. Appay, V., Jandus, C., Voelter, V., Reynard, S., Coupland, S.E., Rimoldi, D., et al. New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site. J. Immunol. 177 (2006), 1670–1678.
87. Sierro, S.R., Donda, A., Perret, R., Guillaume, P., Yagita, H., Levy, F., et al. Combination of lentivector immunization and low-dose chemotherapy or PD-1/PD-L1 blocking primes self-reactive T cells and induces anti-tumor immunity. Eur. J. Immunol. 41 (2011), 2217–2228.
88. van der Most, R.G., Currie, A.J., Cleaver, A.L., Salmons, J., Nowak, A.K., Mahendran, S., et al. Cyclophosphamide chemotherapy sensitizes tumor cells to TRAIL-dependent CD8 T cell-mediated immune attack resulting in suppression of tumor growth. PLoS One, 4, 2009, e6982.
89. Geary, S.M., Lemke, C.D., Lubaroff, D.M., Salem, A.K., The combination of a low-dose chemotherapeutic agent, 5-fluorouracil, and an adenoviral tumor vaccine has a synergistic benefit on survival in a tumor model system. PLoS One, 8, 2013, e67904.
90. Wennerberg, E., Sarhan, D., Carlsten, M., Kaminskyy, V.O., D'Arcy, P., Zhivotovsky, B., et al. Doxorubicin sensitizes human tumor cells to NK cell- and T-cell-mediated killing by augmented TRAIL receptor signaling. Int. J. Cancer 133 (2013), 1643–1652.
91. Yang, S., Haluska, F.G., Treatment of melanoma with 5-fluorouracil or dacarbazine in vitro sensitizes cells to antigen-specific CTL lysis through perforin/granzyme- and Fas-mediated pathways. J. Immunol. 172 (2004), 4599–4608.
92. Aguirre-Ghiso, J.A., Models, mechanisms and clinical evidence for cancer dormancy. Nat. Rev. Cancer 7 (2007), 834–846.
93. Udagawa, T., Tumor dormancy of primary and secondary cancers. APMIS 116 (2008), 615–628.
94. Facciabene, A., Motz, G.T., Coukos, G., T-regulatory cells: key players in tumor immune escape and angiogenesis. Cancer Res. 72 (2012), 2162–2171.
95. Pasquier, E., Kavallaris, M., André, N., Metronomic chemotherapy: new rationale for new directions. Nat. Rev. Clin. Oncol. 7 (2010), 455–465.
96. Cabral, F., Isolation of Chinese hamster ovary cell mutants requiring the continuous presence of taxol for cell division. J. Cell Biol. 97 (1983), 22–29.
97. Schibler, M.J., Cabral, F., Taxol-dependent mutants of Chinese hamster ovary cells with alterations in alpha- and beta-tubulin. J. Cell Biol. 102 (1986), 1522–1531.
98. Kavallaris, M., Kuo, D.Y., Burkhart, C.A., Regl, D.L., Norris, M.D., Haber, M., et al. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J. Clin. Invest. 100 (1997), 1282–1293.
99. Yang, C.P., Verdier-Pinard, P., Wang, F., Lippaine-Horvath, E., He, L., Li, D., et al. A highly epothilone B-resistant A549 cell line with mutations in tubulin that confer drug dependence. Mol. Cancer Ther. 4 (2005), 987–995.
100. Greaves, M., Maley, C.C., Clonal evolution in cancer. Nature 481 (2012), 306–313.
101. Burrella, R.A., Swanton, C., Tumour heterogeneity and the evolution of polyclonal drug resistance. Mol. Oncol. 8 (2014), 1095–1111.
102. Wang, Z., Lu, J., Leaw, S., Hong, X., Wang, J., Shao, Z., et al. An all-oral combination of metronomic cyclophosphamide plus capecitabine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: a phase II study. Cancer Chemother. Pharmacol. 69 (2012), 515–522.
103. Gebbia, V., Serretta, V., Borsellino, N., Valerio, M.R., GSTU Foundation, Salvage therapy with oral metronomic cyclophosphamide and methotrexate for castration-refractory metastatic adenocarcinoma of the prostate resistant to docetaxel. Urology 78 (2011), 1125–1130.
104. Pan, Q., Yang, X.J., Wang, H.M., Dong, X.T., Wang, W., Li, Y., et al. Chemoresistance to temozolomide in human glioma cell line U251 is associated with increased activity of O6-methylguanine-DNA methyltransferase and can be overcome by metronomic temozolomide regimen. Cell Biochem. Biophys. 62 (2012), 185–191.
105. Emmenegger, U., Francia, G., Chow, A., Shaked, Y., Kouri, A., Man, S., et al. Tumors that acquire resistance to low-dose metronomic cyclophosphamide retain sensitivity to maximum tolerated dose cyclophosphamide. Neoplasia 13 (2011), 40–48.
106. De Souza, R., Zahedi, P., Moriyama, E.H., Allen, C.J., Wilson, B.C., Piquette-Miller, M., Continuous docetaxel chemotherapy improves therapeutic efficacy in murine models of ovarian cancer. Mol. Cancer Ther. 9 (2010), 1820–1830.
107. De Souza, R., Zahedi, P., Badame, R.M., Allen, C., Piquette-Miller, M., Chemotherapy dosing schedule influences drug resistance development in ovarian cancer. Mol. Cancer Ther. 10 (2011), 1289–1299.
108. Vassileva, V., Allen, C.J., Piquette-Miller, M., Effects of sustained and intermittent paclitaxel therapy on tumor repopulation in ovarian cancer. Mol. Cancer Ther. 7 (2008), 630–637.
109. Pasquier, E., Tuset, M.P., Street, J., Sinnappan, S., MacKenzie, K.L., Braguer, D., et al. Concentration- and schedule-dependent effects of chemotherapy on the angiogenic potential and drug sensitivity of vascular endothelial cells. Angiogenesis 16 (2013), 373–386.
110. Thoenes, L., Hoehn, M., Kashirin, R., Ogris, M., Arnold, G.J., Wagner, E., et al. In vivo chemoresistance of prostate cancer in metronomic cyclophosphamide therapy. J. Proteomics 73 (2010), 1342–1354.
111. Martin-Padura, I., Marighetti, P., Agliano, A., Colombo, F., Larzabal, L., Redrado, M., et al. Residual dormant cancer stem-cell foci are responsible for tumor relapse after antiangiogenic metronomic therapy in hepatocellular carcinoma xenografts. Lab. Invest. 92 (2012), 952–966.
112. Slaney, C.Y., Rautela, J., Parker, B.S., The emerging role of immunosurveillance in dictating metastatic spread in breast cancer. Cancer Res. 73 (2013), 5852–5857.
113. Pennell, N.A., Understanding the rationale for immunotherapy in non-small cell lung cancer. Semin. Oncol. 42 (2015), S3–S10.
114. Mittal, D., Gubin, M.M., Schreiber, R.D., Smyth, M.J., New insights into cancer immunoediting and its three component phases–elimination, equilibrium and escape. Curr. Opin. Immunol. 27 (2014), 16–25.
115. Saroj, P., Verma, M., Jha, K.K., Pal, M., An overview on immunomodulation. J. Adv. Sci. Res. 3 (2012), 7–12.
116. Hermans, I.F., Chong, T.W., Palmowski, M.J., Harris, A.L., Cerundolo, V., Synergistic effect of metronomic dosing of cyclophosphamide combined with specific antitumor immunotherapy in a murine melanoma model. Cancer Res. 63 (2003), 8408–8413.
117. Chen, C.A., Ho, C.M., Chang, M.C., Sun, W.Z., Chen, Y.L., Chiang, Y.C., et al. Metronomic chemotherapy enhances antitumor effects of cancer vaccine by depleting regulatory T lymphocytes and inhibiting tumor angiogenesis. Mol. Ther. 18 (2010), 1233–1243.
118. Denies, S., Cicchelero, L., Van Audenhove, I., Sanders, N.N., Combination of interleukin-12 gene therapy, metronomic cyclophosphamide and DNA cancer vaccination directs all arms of the immune system towards tumor eradication. J. Control Release 187 (2014), 175–182.
119. Weir, G.M., Hrytsenko, O., Stanford, M.M., Berinstein, N.L., Karkada, M., Liwski, R.S., et al. Metronomic cyclophosphamide enhances HPV16E7 peptide vaccine induced antigen-specific and cytotoxic T-cell mediated antitumor immune response. Oncoimmunology, 3, 2014, e953407.
120. Ouyang, M., White, E.E., Ren, H., Guo, Q., Zhang, I., Gao, H., et al. Metronomic doses of temozolomide enhance the efficacy of carbon nanotube CpG immunotherapy in an invasive glioma model. PLoS One, 11, 2016, e0148139.
121. Lasalvia-Prisco, E., Goldschmidt, P., Galmarini, F., Cucchi, S., Vázquez, J., Aghazarian, M., et al. Addition of an induction regimen of antiangiogenesis and antitumor immunity to standard chemotherapy improves survival in advanced malignancies. Med. Oncol. 29 (2012), 3626–3633.
122. Kandalaft, L.E., Powell, D.J. Jr., Chiang, C.L., Tanyi, J., Kim, S., Bosch, M., et al. Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer. Oncoimmunology, 2, 2013, e22664.
123. Cerullo, V., Diaconu, I., Kangasniemi, L., Rajecki, M., Escutenaire, S., Koski, A., et al. Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus. Mol. Ther. 19 (2011), 1737–1746.
124. Liikanen, I., Ahtiainen, L., Hirvinen, M.L., Bramante, S., Cerullo, V., Nokisalmi, P., et al. Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients. Mol. Ther. 21 (2013), 1212–1223.
125. Ellebaek, E., Engell-Noerregaard, L., Iversen, T.Z., Froesig, T.M., Munir, S., Hadrup, S.R., et al. Metastatic melanoma patients treated with dendritic cell vaccination, Interleukin-2 and metronomic cyclophosphamide: results from a phase II trial. Cancer Immunol. Immunother. 61 (2012), 1791–1804.
126. Soriano, J.L., Batista, N., Santiesteban, E., Lima, M., González, J., García, R., et al. Metronomic cyclophosphamide and methotrexate chemotherapy combined with 1E10 anti-idiotype vaccine in metastatic breast cancer. Int. J. Breast Cancer, 2011, 710292.
127. Walter, B., Schrettenbrunner, I., Vogelhuber, M., Grassinger, J., Bross, K., Wilke, J., et al. Pioglitazone, etoricoxib, interferon-α, and metronomic capecitabine for metastatic renal cell carcinoma: final results of a prospective phase II trial. Med. Oncol. 29 (2012), 799–805.
128. Berinstein, N.L., Karkada, M., Oza, A.M., Odunsi, K., Villella, J.A., Nemunaitis, J.J., et al. Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients. Oncoimmunology, 4, 2015, e1026529.